JP2014094951A5 - - Google Patents

Download PDF

Info

Publication number
JP2014094951A5
JP2014094951A5 JP2014000319A JP2014000319A JP2014094951A5 JP 2014094951 A5 JP2014094951 A5 JP 2014094951A5 JP 2014000319 A JP2014000319 A JP 2014000319A JP 2014000319 A JP2014000319 A JP 2014000319A JP 2014094951 A5 JP2014094951 A5 JP 2014094951A5
Authority
JP
Japan
Prior art keywords
neuregulin
functional fragment
effective amount
neuregulin protein
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014000319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014094951A (ja
JP5964868B2 (ja
Filing date
Publication date
Priority claimed from PCT/CN2002/000349 external-priority patent/WO2003099320A1/en
Application filed filed Critical
Publication of JP2014094951A publication Critical patent/JP2014094951A/ja
Publication of JP2014094951A5 publication Critical patent/JP2014094951A5/ja
Application granted granted Critical
Publication of JP5964868B2 publication Critical patent/JP5964868B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2014000319A 2002-05-24 2014-01-06 心血管疾患を処置するためのニューレギュリン法および組成物 Expired - Lifetime JP5964868B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN02/00349 2002-05-24
PCT/CN2002/000349 WO2003099320A1 (en) 2002-05-24 2002-05-24 Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010223952A Division JP5809789B2 (ja) 2002-05-24 2010-10-01 薬学的組成物、およびキット

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016018132A Division JP6603149B2 (ja) 2002-05-24 2016-02-02 心血管疾患を処置するためのニューレギュリン法および組成物

Publications (3)

Publication Number Publication Date
JP2014094951A JP2014094951A (ja) 2014-05-22
JP2014094951A5 true JP2014094951A5 (enExample) 2014-07-03
JP5964868B2 JP5964868B2 (ja) 2016-08-03

Family

ID=29555543

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2004506824A Pending JP2005532332A (ja) 2002-05-24 2003-05-15 心血管疾患を処置するためのニューレギュリン法および組成物
JP2010223952A Expired - Lifetime JP5809789B2 (ja) 2002-05-24 2010-10-01 薬学的組成物、およびキット
JP2014000319A Expired - Lifetime JP5964868B2 (ja) 2002-05-24 2014-01-06 心血管疾患を処置するためのニューレギュリン法および組成物
JP2016018132A Expired - Lifetime JP6603149B2 (ja) 2002-05-24 2016-02-02 心血管疾患を処置するためのニューレギュリン法および組成物
JP2017214721A Pending JP2018052957A (ja) 2002-05-24 2017-11-07 心血管疾患を処置するためのニューレギュリン法および組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2004506824A Pending JP2005532332A (ja) 2002-05-24 2003-05-15 心血管疾患を処置するためのニューレギュリン法および組成物
JP2010223952A Expired - Lifetime JP5809789B2 (ja) 2002-05-24 2010-10-01 薬学的組成物、およびキット

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016018132A Expired - Lifetime JP6603149B2 (ja) 2002-05-24 2016-02-02 心血管疾患を処置するためのニューレギュリン法および組成物
JP2017214721A Pending JP2018052957A (ja) 2002-05-24 2017-11-07 心血管疾患を処置するためのニューレギュリン法および組成物

Country Status (8)

Country Link
US (4) US7795212B2 (enExample)
EP (2) EP1553960B1 (enExample)
JP (5) JP2005532332A (enExample)
CN (4) CN101007027A (enExample)
AU (3) AU2002304965A1 (enExample)
CA (1) CA2487112C (enExample)
ES (1) ES2627547T3 (enExample)
WO (3) WO2003099320A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US8377114B2 (en) 1999-08-09 2013-02-19 Cardiokinetix, Inc. Sealing and filling ventricular partitioning devices to improve cardiac function
US8500795B2 (en) 1999-08-09 2013-08-06 Cardiokinetix, Inc. Retrievable devices for improving cardiac function
US8257428B2 (en) 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US7674222B2 (en) 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2003101401A2 (en) 2002-06-03 2003-12-11 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
EP1917030A4 (en) * 2005-08-03 2011-03-09 Immunogen Inc IMMUNKONJUGATFORMULIERUNGEN
CA2658326C (en) * 2005-09-02 2013-04-23 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
ES2664086T3 (es) 2005-12-30 2018-04-18 Zensun (Shanghai) Science & Technology, Co., Ltd. Liberación extendida de neurregulina para mejorar la función cardíaca
WO2007130724A2 (en) * 2006-02-06 2007-11-15 Northwind Ventures Systems and methods for volume reduction
AU2008251822B2 (en) * 2007-05-10 2014-02-06 Acorda Therapeutics, Inc. Methods for detecting cardiac damage
CN103432681A (zh) * 2007-05-25 2013-12-11 上海泽生科技开发有限公司 包含神经调节蛋白的药物制剂及装置
CN101310766B (zh) * 2007-05-25 2014-04-16 上海泽生科技开发有限公司 神经调节蛋白的新用途
CN101310765A (zh) * 2007-05-25 2008-11-26 上海泽生科技开发有限公司 神经调节蛋白应用于人的安全剂量
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
JP5797112B2 (ja) * 2008-07-17 2015-10-21 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
ES2609927T3 (es) * 2008-08-15 2017-04-25 Acorda Therapeutics, Inc. Composiciones y métodos para tratamientos durante periodos no agudos después de lesiones neurológicas del SNC
EP2346526A2 (en) 2008-09-22 2011-07-27 Massachusetts Institute of Technology Compositions of and methods of using ligand dimers
CN102232084B (zh) * 2008-11-28 2014-05-28 上海泽生科技开发有限公司 纽兰格林及其用途
CN102231987A (zh) * 2008-11-28 2011-11-02 上海泽生科技开发有限公司 纽兰格林和心脏干细胞
ES2575125T3 (es) 2009-06-09 2016-06-24 Zensun (Shanghai) Science And Technology Limited Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
ES2748886T3 (es) 2009-06-09 2020-03-18 Zensun Shanghai Science & Tech Co Ltd Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
US8889625B2 (en) 2009-07-10 2014-11-18 Northwestern University Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia
US20120121557A1 (en) * 2009-07-22 2012-05-17 Children's Medical Center Corporation Neuregulin induced proliferation of cardiomyocytes
JP6096262B2 (ja) * 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
GB2487339A (en) * 2009-10-23 2012-07-18 Amorcyte Inc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
WO2011056578A2 (en) 2009-10-26 2011-05-12 Cardiokinetix, Inc. Ventricular volume reduction
CN103772498B (zh) * 2009-11-09 2015-07-15 上海泽生科技开发有限公司 纽兰格林及其用途
CN102139095A (zh) * 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
CN104399062A (zh) * 2011-01-11 2015-03-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
MX358408B (es) 2011-03-02 2018-08-20 Berg Llc Ensayos interrogatorios basados en celulas y usos de los mismos.
US8754044B2 (en) 2011-05-03 2014-06-17 Northwestern University Neuroprotection by hepatic cells and hepatocyte secretory factors
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
BR112014024537A2 (pt) 2012-04-02 2017-08-08 Berg Llc métodos para identificar moduladores de um sistema biológico, de um processo de doença, e de angiogênese
CN104487842B (zh) 2012-05-22 2017-09-08 博格有限责任公司 用于鉴别药物诱导毒性标志物的基于细胞的探询式分析
CN104781670B (zh) 2012-09-12 2017-07-07 博格有限责任公司 标志物用于识别心脏毒性剂的用途
WO2014051567A1 (en) * 2012-09-26 2014-04-03 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
EP2903632A4 (en) 2012-10-08 2016-07-13 Zensun Shanghai Science And Technology Ltd COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN DIABETES PATIENTS
ES2743617T3 (es) 2013-05-22 2020-02-20 Zensun Shanghai Science & Tech Co Ltd Liberación prolongada de neuregulina para tratar la insuficiencia cardíaca
CA2925723A1 (en) * 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
EA035289B1 (ru) 2013-10-18 2020-05-25 Аттоквант Диагностикс Гмбх Способ диагностики первичного гиперальдостеронизма
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
US20170035848A1 (en) 2014-04-15 2017-02-09 Universiteit Antwerpen Treatment of nephropathy
CN107111603A (zh) 2014-09-11 2017-08-29 博格有限责任公司 基于患者数据的用于健康护理诊断和治疗的贝叶斯因果关系网络模型
CN105497876B (zh) * 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
WO2016048802A1 (en) 2014-09-28 2016-03-31 Cardiokinetix, Inc. Apparatuses for treating cardiac dysfunction
CN111407882A (zh) * 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
US20170333529A1 (en) * 2015-01-20 2017-11-23 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
CN104922153A (zh) * 2015-04-02 2015-09-23 连祺周 Nrg1-erbb4复合体在制备治疗心肌缺血的药物中的应用
US10017574B2 (en) * 2015-05-07 2018-07-10 Yeda Research And Development Co. Ltd. Methods, kits and devices for promoting cardiac regeneration
US10758560B2 (en) 2015-12-22 2020-09-01 Societe Des Produits Nestle S.A. Methods for treating sarcopenia and frailty
US10898330B2 (en) 2017-03-28 2021-01-26 Edwards Lifesciences Corporation Positioning, deploying, and retrieving implantable devices
MX2020010740A (es) * 2018-04-11 2021-01-20 Salubris Biotherapeutics Inc Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso.
CN111407881A (zh) * 2019-01-07 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
AR121035A1 (es) * 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CN109999015A (zh) * 2019-04-24 2019-07-12 江苏省中医药研究院 紫草素在制备预防或治疗房颤药物中的用途
EP4032901A4 (en) 2019-09-16 2023-10-25 Zensun (Shanghai) Science & Technology, Co., Ltd. RECOMBINANT HUMAN NEUREGULIN DERIVATIVES AND THEIR USE
CN110714068A (zh) * 2019-11-14 2020-01-21 南通大学 膜蛋白分子ErbB4在制备治疗脑缺血损伤药物中的应用
CN113289002A (zh) 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
CN113238060B (zh) * 2021-05-08 2022-10-11 迈克生物股份有限公司 用于预测或诊断心肌炎的试剂盒
WO2023070078A1 (en) * 2021-10-22 2023-04-27 The Research Institute At Nationwide Children's Hospital Neuregulin for protection against respiratory viral infection and post-viral disease

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
EP0091539B2 (en) 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
DE3220116A1 (de) 1982-05-28 1983-12-01 Dr. Karl Thomae Gmbh, 7950 Biberach Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE159858T1 (de) 1983-09-26 1997-11-15 Ehrenfeld Udo Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1989001489A1 (en) 1987-08-10 1989-02-23 Commonwealth Scientific And Industrial Research Or Control of angiogenesis and compositions and methods therefor
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
JPH02226533A (ja) 1989-02-27 1990-09-10 Mitsubishi Electric Corp 情報記録媒体
GB9107566D0 (en) 1991-04-10 1991-05-29 Ludwig Inst Cancer Res Glial mitogenic factors,their preparation and use
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5367060A (en) 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
PL176408B1 (pl) 1992-02-10 1999-05-31 Interferon Sciences Inc Kompozycja naturalnego alfa interferonu z ludzkich leukocytów krwi obwodowej i sposób wytwarzania kompozycji naturalnego alfa interferonu z ludzkich leukocytów krwi obwodowej
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
DE4221256C2 (de) 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
CA2126619A1 (en) 1993-06-24 1994-12-25 Yasutaka Igari Sustained-release preparation of anti-endothelin substance
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US5399699A (en) 1994-01-24 1995-03-21 Abbott Laboratories Indole iminooxy derivatives which inhibit leukotriene biosynthesis
EP1104809A1 (en) 1994-04-09 2001-06-06 F. Hoffmann-La Roche Ag Process for producing alpha-interferon
US5770567A (en) 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
WO1996028548A1 (en) 1995-03-10 1996-09-19 Genentech, Inc. Receptor activation by gas6
US6750196B1 (en) * 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5741511A (en) 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
US6033660A (en) 1995-05-10 2000-03-07 Genentech, Inc. Method of treating a nervous system injury with cultured schwann cells
US5714385A (en) 1995-05-10 1998-02-03 Genentech, Inc. Media for culturing schwann cells
US5721139A (en) 1995-05-10 1998-02-24 Genentech, Inc. Isolating and culturing schwann cells
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
US5941868A (en) 1995-12-22 1999-08-24 Localmed, Inc. Localized intravascular delivery of growth factors for promotion of angiogenesis
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US5834235A (en) 1996-06-21 1998-11-10 Health Research, Incorporated Inferferon-α-induced protein
AU722178B2 (en) 1996-07-12 2000-07-27 Genentech Inc. Chimeric heteromultimer adhesins
AU727606B2 (en) 1996-07-12 2000-12-14 Genentech Inc. Gamma-heregulin
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US20020002276A1 (en) 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
CA2278151C (en) 1997-02-10 2010-11-16 Genentech, Inc. Heregulin variants
WO1998055611A1 (en) 1997-06-06 1998-12-10 Regents Of The University Of Michigan Neuregulin response element and uses therefor
US6121415A (en) 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
SE9703226D0 (sv) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
EP1028735A4 (en) 1997-10-14 2003-08-06 Cenes Pharmaceuticals Inc THERAPEUTIC METHOD COMPRISING THE USE OF NEUREGULIN
US6197801B1 (en) 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
US5962274A (en) 1998-03-13 1999-10-05 Wake Forest University Viral vector directed to predetermined target cells
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6446242B1 (en) 1999-04-02 2002-09-03 Actel Corporation Method and apparatus for storing a validation number in a field-programmable gate array
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US6933122B1 (en) 1999-05-14 2005-08-23 The Trustees Of Columbia University In The City Of New York A-form of cytoplasmic domain of nARIA (CRD-neuregulin) and uses thereof
CN1138785C (zh) * 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
US6602851B1 (en) 1999-10-08 2003-08-05 Uab Research Foundation SMDF and GGF neuregulin splice variant isoforms and uses thereof
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
ES2252216T3 (es) 2000-02-11 2006-05-16 Proteosys Ag Utilizacion de neorregulina-beta como indicador y/o diana.
AU2001241838A1 (en) 2000-02-28 2001-09-12 Decode Genetics Ehf Human schizophrenia gene
US20020045577A1 (en) * 2000-02-28 2002-04-18 Decode Genetics Human schizophrenia gene
US6544759B1 (en) 2000-04-21 2003-04-08 Yeda Research And Development Co. Ltd Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
CN1498656A (zh) 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
JP2004348674A (ja) * 2003-05-26 2004-12-09 Noritsu Koki Co Ltd 領域検出方法及びその装置
CN1715926B (zh) 2004-07-02 2011-08-17 上海泽生科技开发有限公司 神经调节蛋白突变体的应用
CN1743005A (zh) 2004-09-02 2006-03-08 上海泽生科技开发有限公司 Pi3－k抑制剂的新用途及组合物
CN1743006A (zh) 2004-09-02 2006-03-08 上海泽生科技开发有限公司 Mapk抑制剂的新用途及组合物
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
ES2664086T3 (es) 2005-12-30 2018-04-18 Zensun (Shanghai) Science & Technology, Co., Ltd. Liberación extendida de neurregulina para mejorar la función cardíaca
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation

Similar Documents

Publication Publication Date Title
JP2014094951A5 (enExample)
IL285782A (en) Compounds, compositions, and methods for treating disease
JP2016041733A5 (enExample)
IL263425A (en) Antagonistic t-linked antibodies to human tgfb2, tgfb1 and tgfb3 and their use for the treatment of pulmonary fibrosis
MX2021002322A (es) Nuevos metodos.
JP2017532343A5 (enExample)
MX2018003206A (es) Moduladores de la proteína del núcleo de la hepatitis b.
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
MX2016009975A (es) Derivados de dihidropteridinona y sus usos.
IL290792A (en) Preparations and methods for treating viral infections
JP2014051497A5 (enExample)
PH12018550026A1 (en) Acetamide thienotriazoldiazepines and uses thereof
WO2017044849A8 (en) Cyano thienotriazolodiazepines and uses thereof
JP2015517488A5 (enExample)
EA201791903A1 (ru) β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
JP2015535243A5 (enExample)
JP2016116527A5 (enExample)
WO2016022970A8 (en) Dihydropteridinone derivatives and uses thereof
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
WO2017029558A3 (en) Methods for improving health of farmed fish
WO2016142708A3 (en) Pharmaceutical composition
CA3010708A1 (en) Methods of administering hepcidin
CA3128691C (en) Methods of improving myocardial performance in fontan patients using udenafil compositions
WO2016090107A3 (en) Treatment of hepatitis delta virus infection
JP2016522188A5 (enExample)